A Weight-Loss Shot Eased Knee Arthritis Pain in a Large Trial

Knee arthritis made headlines this week. On September 29, 2026, the New England Journal of Medicine published results from a large trial of retatrutide, an experimental weight-loss drug from Eli Lilly. Among 574 participants who had knee osteoarthritis, pain scores fell more on the drug than on placebo^[1]. The trial was about obesity, not arthritis. But the knee pain finding is real, and worth understanding.

What the Trial Found

The trial, called TRIUMPH-1, enrolled 2,339 adults with obesity who did not have diabetes, across 131 sites in 11 countries. Participants received a once-weekly shot of retatrutide (4, 9, or 12 mg) or placebo for 80 weeks^[1]. Retatrutide mimics three gut and metabolic hormones at once: GLP-1, GIP, and glucagon^[4].

The headline results:

• Weight: participants lost 17.6%, 23.7%, and 25.0% of body weight at the three doses, versus 3.9% on placebo^[1].
• Knee pain: among the 574 with knee osteoarthritis, WOMAC knee pain scores (rated 0 to 10) fell 3.2, 3.5, and 3.6 points, versus 1.9 points on placebo^[2].
• Sleep apnea: hourly breathing interruptions fell by 23 to 34 events on the drug, versus about 10 on placebo^[2].

Why the Knees Likely Felt Better

The researchers did not claim the drug repairs joints. The most likely explanation is the weight loss itself. Less body weight means less load on the knees with every step. Extra weight is a known driver of knee osteoarthritis: orthopedic surgeon Dr. Abby Cheng of Washington University notes that being overweight or obese raises a person's risk for knee osteoarthritis^[3].

This matters because the benefit may come from pounds lost, not from the drug acting on the joint. The trial was not designed to answer that question, so it is still open.

What It Is Not

Some important limits on the news:

• Not approved. Retatrutide is investigational. No doctor can prescribe it yet^[4].
• Not an arthritis drug. It is being developed for obesity. The trial enrolled people with obesity, and the knee results came from a planned group of 574 participants within that trial^[2].
• Not compared with other weight-loss drugs. The trial did not test it head to head against tirzepatide or similar medicines^[4].
• Not side-effect free. The most common side effects were stomach and gut symptoms such as nausea, familiar from the GLP-1 drug family. Rarer risks need longer study^[4].
• Paid for by the maker. Eli Lilly, which makes retatrutide, funded the trial^[2].

What This Means If Your Knees Hurt

If you have knee osteoarthritis, this is genuinely encouraging news about where treatment is heading. But the drug is not available, and approval takes time. Weight loss of any kind that you can keep off remains one of the best-studied ways to ease knee pain.

LDRT is a different path: a non-drug treatment for knee arthritis pain, available now at programs across the country. It does not depend on weight loss and does not involve daily medication. If your knees hurt today, talk to your doctor about which options fit your situation.

References:
1. Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo. HCPLive, September 29, 2026 (reporting Jastreboff AM, et al., TRIUMPH-1, New England Journal of Medicine). HCPLive
2. Retatrutide Reduced Pain, Sleep Apnea in Adults With Obesity. Psychiatric News Alert, October 1, 2026 (reporting TRIUMPH-1, funded by Eli Lilly). Psychiatric News Alert
3. Tips for treating, even preventing, osteoarthritis. MedicalXpress, August 2026 (Dr. Abby Cheng, Washington University School of Medicine). MedicalXpress
4. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, published online September 29, 2026. DOI: 10.1056/NEJMoa2604169. NEJM